AURO-SUNITINIB CAPSULE
País: Canadà
Idioma: anglès
Font: Health Canada
Fitxa tècnica
(SPC)
24-10-2022
Alguns documents d’aquest producte actualment no estan disponibles, podeu enviar una sol·licitud al nostre servei d’atenció al client i us ho notificarem tan bon punt puguem obtenir-los.
Enviar sol.licitud.
Enviar sol.licitud.
ingredients actius:
SUNITINIB (SUNITINIB MALATE)
Disponible des:
AURO PHARMA INC
Codi ATC:
L01EX01
Designació comuna internacional (DCI):
SUNITINIB
Dosis:
12.5MG
formulario farmacéutico:
CAPSULE
Composición:
SUNITINIB (SUNITINIB MALATE) 12.5MG
Vía de administración:
ORAL
Unidades en paquete:
15G/50G
tipo de receta:
Prescription
Resumen del producto:
Active ingredient group (AIG) number: 0151642001; AHFS:
Estat d'Autorització:
APPROVED
Data d'autorització:
2022-11-18
Fitxa tècnica
Page 1 of 66
PRODUCT MONOGRAPH
PR
AURO-SUNITINIB
Sunitinib Capsules
12.5 mg, 25 mg, 37.5 mg, 50 mg
Sunitinib
(as sunitinib malate)
Tyrosine Kinase Inhibitor,
Anti-Tumour Agent
AURO PHARMA INC. DATE OF PREPARATION:
3700 Steeles Avenue West, Suite # 402 October 24, 2022
Woodbridge, Ontario, L4L 8K8,
Canada.
Submission
Control No: 249322
Page 2 of 66
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................. 3
SUMMARY PRODUCT
INFORMATION..................................................................3
INDICATIONS AND CLINICAL USE
.......................................................................3
CONTRAINDICATIONS
...........................................................................................4
WARNINGS AND PRECAUTIONS
...........................................................................4
ADVERSE REACTIONS
.........................................................................................
17
DRUG INTERACTIONS
.........................................................................................
30
DOSAGE AND ADMINISTRATION
......................................................................
31
OVERDOSAGE
......................................................................................................
32
ACTION AND CLINICAL PHARMACOLOGY
...................................................... 32
STORAGE AND STABILITY
.................................................................................
36
SPECIAL HANDLING INSTRUCTIONS
................................................................ 36
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................ 37
PART II: SCIENTIFIC INFORMATION
......................................................................
38
PHARMACEUTICAL INFORMATION
.................................................................. 38
CLINICAL TRIALS
................................................................................................
39
DETAILED PHARMACOLOGY
.................
Llegiu el document complet
